Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Edward P. Armstrong, Daniel C. Malone, Sangeeta Krishnan & Maj Jacob Wessler. (2015) Adherence to clotting factors among persons with hemophilia A or B. Hematology 20:3, pages 148-153.
Read now
Read now
Hans-Christoph Rossbach. (2010) Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. Vascular Health and Risk Management 6, pages 59-68.
Read now
Read now
Leonard A Valentino, Yousef Ismael & Michele Grygotis. (2010) Novel drugs to treat hemophilia. Expert Opinion on Emerging Drugs 15:4, pages 597-613.
Read now
Read now
Articles from other publishers (25)
Santiago Bonanad, María García‐Dasí, José A. Aznar, María Eva Mingot‐Castellano, Victor Jiménez‐Yuste, MªVictoria Calle, Antonio Palma, María Fernanda López‐Fernández, Pascual Marco, María José Paloma, Nuria Fernández‐Mosteirin, Bernat Galmés, Martín Sanabria & MªPilar Álvarez. (2020) Adherence to prophylaxis in adult patients with severe haemophilia A. Haemophilia 26:5, pages 800-808.
Crossref
Crossref
Jayashree Motwani, Benoit Guillet, Jan Blatny, Freimut H. Schilling, Bénédicte Wibaut, Jimena Goldstine, Andras Nagy, Jennifer Doralt, Werner Engl, Srilatha Tangada & Gerald Spotts. (2020) Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A. Haemophilia 26:3, pages 478-486.
Crossref
Crossref
Mario Schiavoni, Mariasanta Napolitano, Gaetano Giuffrida, Antonella Coluccia, Sergio Siragusa, Valeria Calafiore, Giuseppe Lassandro & Paola Giordano. (2019) Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits. Frontiers in Medicine 6.
Crossref
Crossref
A. D. Shapiro, J. N. Mahlangu, D. Perry, J. Pasi, D. V. Quon, P. Chowdary, E. Tsao, S. Li, A. Innes, G. F. Pierce & G. A. Allen. (2017) Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia 23:3, pages 392-399.
Crossref
Crossref
A. Iorio, A.M. Barbara, F. Bernardi, D. Lillicrap, M. Makris, F. Peyvandi & F. Rosendaal. (2016) Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 14:8, pages 1668-1672.
Crossref
Crossref
B. Brand, R. Gruppo, T. T. Wynn, L. Griskevicius, M. F. Lopez Fernandez, M. Chapman, T. Dvorak, B. G. Pavlova & B. E. Abbuehl. (2016)
Efficacy and safety of pegylated full‐length recombinant factor
VIII
with extended half‐life for perioperative haemostasis in haemophilia A patients
. Haemophilia 22:4.
Crossref
Crossref
L. H. Schrijvers, M. J. Schuurmans & K. Fischer. (2016) Promoting self‐management and adherence during prophylaxis: evidence‐based recommendations for haemophilia professionals. Haemophilia 22:4, pages 499-506.
Crossref
Crossref
Tamara Pérez-Robles, José A. Romero-Garrido, E. Carlos Rodriguez-Merchan & Alicia Herrero-Ambrosio. (2016) Objective quantification of adherence to prophylaxis in haemophilia patients aged 12 to 25years and its potential association with bleeding episodes. Thrombosis Research 143, pages 22-27.
Crossref
Crossref
A. D. Shapiro, C. Schoenig‐Diesing, L. Silvati‐Fidell, W. Y. Wong & V. Romanov. (2015)
Integrated analysis of safety data from 12 clinical interventional studies of plasma‐ and albumin‐free recombinant factor VIII (r
AHF
‐
PFM
) in haemophilia A
. Haemophilia 21:6, pages 791-798.
Crossref
Crossref
Barbara A. KonkleOleksandra StasyshynPratima ChowdaryDavid H. BevanTim MantMidori ShimaWerner Engl, Jacqueline Dyck-Jones, Monika Fuerlinger, Lisa Patrone, Bruce Ewenstein & Brigitt Abbuehl. (2015) Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 126:9, pages 1078-1085.
Crossref
Crossref
M. García-Dasí, J. A. Aznar, V. Jiménez-Yuste, C. Altisent, S. Bonanad, E. Mingot, F. Lucía, F. Giménez, M. Fernanda López, P. Marco, R. Pérez, M. Á. Fernández, M. J. Paloma, B. Galmes, S. Herrero & J. A. García-Talavera. (2015) Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia 21:4, pages 458-464.
Crossref
Crossref
Xunwei Duan, Mingqing Tang, Junping Zhang, Hao Yu & Ruian Xu. (2014) Promising coagulation factor VIII bypassing strategies for patients with haemophilia A. Blood Coagulation & Fibrinolysis 25:6, pages 539-552.
Crossref
Crossref
S. V. Antunes, S. Tangada, O. Stasyshyn, V. Mamonov, J. Phillips, N. Guzman‐Becerra, A. Grigorian, B. Ewenstein & W.‐Y. Wong. (2013)
Randomized comparison of prophylaxis and on‐demand regimens with
FEIBA NF
in the treatment of haemophilia A and B with inhibitors
. Haemophilia 20:1, pages 65-72.
Crossref
Crossref
S. Ho, D. Gue, K. McIntosh, M. Bucevska, M. Yang & S. Jackson. (2013) An objective method for assessing adherence to prophylaxis in adults with severe haemophilia. Haemophilia 20:1, pages 39-43.
Crossref
Crossref
Matthew P. Kosloski, Dipak S. Pisal, Donald E. Mager & Sathy V. Balu-Iyer. (2013) Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins. Journal of Pharmaceutical Sciences 102:7, pages 2380-2394.
Crossref
Crossref
Hartmut Pollmann, Robert Klamroth, Natascha Vidovic, Alexander Y. Kriukov, Joshua Epstein, Ingo Abraham, Gerald Spotts & Johannes Oldenburg. (2013) Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study. Annals of Hematology 92:5, pages 689-698.
Crossref
Crossref
Gillian M. Keating & Sohita Dhillon. (2012) Octocog Alfa (Advate®): A Guide to Its Use in Hemophilia A. BioDrugs 26:4, pages 269-273.
Crossref
Crossref
Sohita Dhillon. (2012) Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®). Drugs 72:7, pages 987-1007.
Crossref
Crossref
M. FRANCHINI, M. MAKRIS, E. SANTAGOSTINO, A. COPPOLA & P. M. MANNUCCI. (2012) Non‐thrombotic‐, non‐inhibitor‐associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand’s disease: a systematic review of prospective studies. Haemophilia 18:3.
Crossref
Crossref
G. Auerswald, A. Thompson, M. Recht, D. Brown, R. Liesner, N. Guzman-Becerra, J. Dyck-Jones, B. Ewenstein & B. Abbuehl. (2012) Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thrombosis and Haemostasis 107:6, pages 1072-1082.
Crossref
Crossref
L.A. VALENTINO, V. MAMONOV, A. HELLMANN, D.V. QUON, A. CHYBICKA, P. SCHROTH, L. PATRONE & W.‐Y. WONG. (2012) A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis 10:3, pages 359-367.
Crossref
Crossref
L.M. ALEDORT, R.J. NAVICKIS & M.M. WILKES. (2011) Best evidence on B‐domain deletion and the immunogenicity of recombinant factor VIII. Journal of Thrombosis and Haemostasis 9:11, pages 2325-2327.
Crossref
Crossref
L.M. ALEDORT, R.J. NAVICKIS & M.M. WILKES. (2011) Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studies. Journal of Thrombosis and Haemostasis 9:11, pages 2180-2192.
Crossref
Crossref
J. OLDENBURG, J. GOUDEMAND, L. VALENTINO, M. RICHARDS, H. LUU, A. KRIUKOV, H. GAJEK, G. SPOTTS & B. EWENSTEIN. (2010) Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practice. Haemophilia 16:6, pages 866-877.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:9.
Crossref
Crossref